Auto-Induction in Oral Esketamine Treatment for Treatment-Resistant Depression: An Exploratory Study.
Pharmaceuticals (Basel, Switzerland) April 25, 2025 Jolien K E Veraart, Cornelis F Vos, Nieko C Punt et al. 2 citations
Background: Esketamine is a rapidly acting antidepressant with robust efficacy in treatment-resistant depression (TRD). Diminishing therapeutic effects and attenuated side effects have been reported after long-term use. This study aimed to investigate its long-term pharmacokinetics and factors that may contribute to reduced efficacy over time in patients with TRD by evaluating the potential...